Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.38 |
| ▸ | CHRNG | P07510 | 2/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.38 |
| ▸ | CHRND | Q07001 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17846148 | 0.84 | HRH1 (0.47) | HTR2AHRH1 | |
| SCHEMBL17846149 | 0.82 | HRH1 (0.53) | HTR2AHRH1 | |
| SCHEMBL10323207 | 0.79 | HRH1 (0.50) | HTR2AHRH1 | |
| SCHEMBL25270433 | 0.76 | ALDH1A1 (0.45) | — | |
| SCHEMBL1953141 | 0.75 | TAS1R3 (0.51) | — | |
| SCHEMBL115980 | 0.72 | ROCK1 (0.55) | HTR2A | |
| SCHEMBL4598191 | 0.72 | ROCK1 (0.55) | HTR2A | |
| SCHEMBL9403960 | 0.71 | UTS2R (0.55) | ITGB3ITGA2B | |
| SCHEMBL12561309 | 0.71 | HTR2A (0.47) | HTR2AHRH1 | |
| SCHEMBL13493127 | 0.71 | HTR2A (0.47) | HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
| EP-2013183-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124898-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS, ALMIRALL S.A. (ES) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | TLR2 393/4885ITGB3 939/4885ITGA2B 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.